Patricia A Thompson1, Erin L Ashbeck1, Denise J Roe1, Liane Fales1, Julie Buckmeier1, Fang Wang1, Achyut Bhattacharyya1, Chiu-Hsieh Hsu1, Sherry H H Chow1, Dennis J Ahnen1, C Richard Boland1, Russell I Heigh1, David E Fay1, Stanley R Hamilton1, Elizabeth T Jacobs1, Elena Maria Martinez1, David S Alberts1, Peter Lance2. 1. University of Arizona Cancer Center, Tucson, AZ (PAT, ELA, DJR, LF, JB, FW, CHH, HHSC, ETJ, DSA, PL); Department of Pathology, University of Arizona, Tucson, AZ (AB); Denver Department of Veterans Affairs Medical Center and University of Colorado, Denver, CO (DJA); GI Cancer Research Laboratory, Baylor University Medical Center, Dallas, TX (CRB); Division of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ (RIH); Endoscopy Center of Western New York, Buffalo, NY (DEF); Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (SRH); Moores UCSD Cancer Center, San Diego, CA (MEM). Current affiliation: Stony Brook University, Stony Brook, New York, NY (PAT). 2. University of Arizona Cancer Center, Tucson, AZ (PAT, ELA, DJR, LF, JB, FW, CHH, HHSC, ETJ, DSA, PL); Department of Pathology, University of Arizona, Tucson, AZ (AB); Denver Department of Veterans Affairs Medical Center and University of Colorado, Denver, CO (DJA); GI Cancer Research Laboratory, Baylor University Medical Center, Dallas, TX (CRB); Division of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ (RIH); Endoscopy Center of Western New York, Buffalo, NY (DEF); Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (SRH); Moores UCSD Cancer Center, San Diego, CA (MEM). Current affiliation: Stony Brook University, Stony Brook, New York, NY (PAT). plance@uacc.arizona.edu.
Abstract
BACKGROUND:Cyclooxygenase (COX)-2 inhibitors such as celecoxib were designed to preserve anti-inflammatory activity without inhibiting COX-1. Downregulation of COX-2 inhibits colorectal carcinogenesis. METHODS: The Selenium and Celecoxib Trial was a randomized, placebo-controlled trial of once-daily selenium 200 µg and celecoxib 400 mg, alone or together, for colorectal adenoma prevention. Men and women between age 40 and 80 years were eligible following colonoscopic removal of adenomas. The primary outcome was development of new adenomas. Celecoxib was suspended early because of cardiovascular toxicity in other trials. Accrual to selenium or placebo continued. Before suspension, 824 participants were randomly assigned to celecoxib or placebo, of whom 712 (86.4%) were available for analysis. All statistical tests were two-sided. RESULTS: In the placebo and celecoxib arms of 356 participants each, adenoma detection was 47.5% and 49.7% (relative risk [RR] = 1.04, 95% confidence interval [CI] = 0.90 to 1.21, P = .58), respectively, after median periods of 13.6 and 14.2 months on intervention. Among participants colonoscoped within 12 months of discontinuing intervention (n = 244), overall adenoma recurrence (RR = 0.69, 95% CI = 0.48 to 0.98, P = .04) and recurrence with advanced adenomas (RR = 0.23, 95% CI = 0.07 to 0.80, P = .02) were reduced with celecoxib. Reduction of adenoma recurrence was greatest in participants with previous advanced adenomas. Celecoxib increased risk of hypertension in participants with pre-existing cardiovascular risk factors compared with placebo (hazard ratio = 2.19, 95% CI = 1.07 to 4.50, P = .03). CONCLUSIONS: Limited-duration celecoxib prevents adenoma recurrence in patients with prior high-risk adenomas, in whom strategies to minimize cardiovascular toxicity might be feasible.
RCT Entities:
BACKGROUND: Cyclooxygenase (COX)-2 inhibitors such as celecoxib were designed to preserve anti-inflammatory activity without inhibiting COX-1. Downregulation of COX-2 inhibits colorectal carcinogenesis. METHODS: The Selenium and Celecoxib Trial was a randomized, placebo-controlled trial of once-daily selenium 200 µg and celecoxib 400 mg, alone or together, for colorectal adenoma prevention. Men and women between age 40 and 80 years were eligible following colonoscopic removal of adenomas. The primary outcome was development of new adenomas. Celecoxib was suspended early because of cardiovascular toxicity in other trials. Accrual to selenium or placebo continued. Before suspension, 824 participants were randomly assigned to celecoxib or placebo, of whom 712 (86.4%) were available for analysis. All statistical tests were two-sided. RESULTS: In the placebo and celecoxib arms of 356 participants each, adenoma detection was 47.5% and 49.7% (relative risk [RR] = 1.04, 95% confidence interval [CI] = 0.90 to 1.21, P = .58), respectively, after median periods of 13.6 and 14.2 months on intervention. Among participants colonoscoped within 12 months of discontinuing intervention (n = 244), overall adenoma recurrence (RR = 0.69, 95% CI = 0.48 to 0.98, P = .04) and recurrence with advanced adenomas (RR = 0.23, 95% CI = 0.07 to 0.80, P = .02) were reduced with celecoxib. Reduction of adenoma recurrence was greatest in participants with previous advanced adenomas. Celecoxib increased risk of hypertension in participants with pre-existing cardiovascular risk factors compared with placebo (hazard ratio = 2.19, 95% CI = 1.07 to 4.50, P = .03). CONCLUSIONS: Limited-duration celecoxib prevents adenoma recurrence in patients with prior high-risk adenomas, in whom strategies to minimize cardiovascular toxicity might be feasible.
Authors: Nadir Arber; Craig J Eagle; Julius Spicak; István Rácz; Petr Dite; Jan Hajer; Miroslav Zavoral; Maria J Lechuga; Paola Gerletti; Jie Tang; Rebecca B Rosenstein; Katie Macdonald; Pritha Bhadra; Robert Fowler; Janet Wittes; Ann G Zauber; Scott D Solomon; Bernard Levin Journal: N Engl J Med Date: 2006-08-31 Impact factor: 91.245
Authors: Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron Journal: N Engl J Med Date: 2005-02-15 Impact factor: 91.245
Authors: Patricia Thompson; Denise J Roe; Liane Fales; Julie Buckmeier; Fang Wang; Stanley R Hamilton; Achyut Bhattacharyya; Sylvan Green; Chiu-Hsieh Hsu; H-H Sherry Chow; Dennis J Ahnen; C Richard Boland; Russell I Heigh; David E Fay; Maria Elena Martinez; Elizabeth Jacobs; Erin L Ashbeck; David S Alberts; Peter Lance Journal: Cancer Prev Res (Phila) Date: 2012-10-11
Authors: H-H Sherry Chow; Nathan Anavy; Dawn Salazar; Denise H Frank; David S Alberts Journal: J Pharm Biomed Anal Date: 2004-01-27 Impact factor: 3.935
Authors: Erica A Golemis; Paul Scheet; Tim N Beck; Eward M Scolnick; David J Hunter; Ernest Hawk; Nancy Hopkins Journal: Genes Dev Date: 2018-06-26 Impact factor: 11.361
Authors: Patricia A Thompson; Erin L Ashbeck; Denise J Roe; Liane Fales; Julie Buckmeier; Fang Wang; Achyut Bhattacharyya; Chiu-Hsieh Hsu; H H Sherry Chow; Dennis J Ahnen; C Richard Boland; Russell I Heigh; David E Fay; Stanley R Hamilton; Elizabeth T Jacobs; Maria Elena Martinez; David S Alberts; Peter Lance Journal: J Natl Cancer Inst Date: 2016-08-16 Impact factor: 13.506
Authors: Emerson Y Chen; Charles D Blanke; Daniel G Haller; Al B Benson; Tomislav Dragovich; Heinz-Josef Lenz; Carlos Robles; Hong Li; Motomi Mori; Nora Mattek; Rachel E Sanborn; Charles D Lopez Journal: Am J Clin Oncol Date: 2018-12 Impact factor: 2.339
Authors: Jane C Figueiredo; Eric J Jacobs; Christina C Newton; Mark A Guinter; William G Cance; Peter T Campbell Journal: J Natl Cancer Inst Date: 2021-07-01 Impact factor: 13.506
Authors: Alberto Izzotti; Sebastiano La Maestra; Rosanna T Micale; Alessandra Pulliero; Marta Geretto; Roumen Balansky; Silvio De Flora Journal: Oncotarget Date: 2018-09-14
Authors: Jessica A Martinez; Jun Yang; Betsy C Wertheim; Denise J Roe; Alexander Schriewer; Peter Lance; David S Alberts; Bruce D Hammock; Patricia A Thompson Journal: PLoS One Date: 2018-04-26 Impact factor: 3.240